[
  {
    "ts": null,
    "headline": "Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?",
    "summary": "EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.",
    "url": "https://finnhub.io/api/news?id=275a99752d246814df37eb1a656e0a8367f8a752db65e353e3db30575670f2b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751894520,
      "headline": "Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?",
      "id": 135787060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.",
      "url": "https://finnhub.io/api/news?id=275a99752d246814df37eb1a656e0a8367f8a752db65e353e3db30575670f2b8"
    }
  },
  {
    "ts": null,
    "headline": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "url": "https://finnhub.io/api/news?id=7ce58edbd36c5260715bc3ad1d0defa527f8036559ed90ac2eb3f61a9c2bee2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751893802,
      "headline": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks",
      "id": 135788437,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
      "url": "https://finnhub.io/api/news?id=7ce58edbd36c5260715bc3ad1d0defa527f8036559ed90ac2eb3f61a9c2bee2d"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know",
    "summary": "Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=2055479f0d8d89ece191f05b70f17842a96720ca9784d3d81b8581b7a6d6b22b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751893202,
      "headline": "Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know",
      "id": 135788689,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=2055479f0d8d89ece191f05b70f17842a96720ca9784d3d81b8581b7a6d6b22b"
    }
  },
  {
    "ts": null,
    "headline": "SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca",
    "summary": "Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.",
    "url": "https://finnhub.io/api/news?id=95ab97e8c26970002d21d0f53643681754ce3916cdf4b9418ddc03aa5fa72b6e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751892720,
      "headline": "SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca",
      "id": 135786237,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.",
      "url": "https://finnhub.io/api/news?id=95ab97e8c26970002d21d0f53643681754ce3916cdf4b9418ddc03aa5fa72b6e"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co.: A Pharma Titan At A Discount",
    "summary": "Merck & Co. may be down YTD, but strong pipeline growth and my DCF show a 23% upside.",
    "url": "https://finnhub.io/api/news?id=335939a1b00d3e76567e031851ef1ace933b4319183b322c5a17c6f23ceaecf7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751892497,
      "headline": "Merck & Co.: A Pharma Titan At A Discount",
      "id": 135787242,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Merck & Co. may be down YTD, but strong pipeline growth and my DCF show a 23% upside.",
      "url": "https://finnhub.io/api/news?id=335939a1b00d3e76567e031851ef1ace933b4319183b322c5a17c6f23ceaecf7"
    }
  },
  {
    "ts": null,
    "headline": "2 Wonderful Dividends At Bargain Basement Prices",
    "summary": "2 Wonderful Dividends At Bargain Basement Prices",
    "url": "https://finnhub.io/api/news?id=8f0d2e77e19b3b7cbfac840164e6e427f2f55e0461cebe8ad53b7b4d5e2790e8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751888700,
      "headline": "2 Wonderful Dividends At Bargain Basement Prices",
      "id": 135786717,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8f0d2e77e19b3b7cbfac840164e6e427f2f55e0461cebe8ad53b7b4d5e2790e8"
    }
  },
  {
    "ts": null,
    "headline": "Onco360 Has Been Selected as a National Specialty Pharmacy for Augtyro™ (repotrectinib)",
    "summary": "LOUISVILLE, Ky., July 07, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol Myers Squibb to its comprehensive list of limited distribution therapies. Augtyro was initially approved on November 15, 2023, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). In June 2024, Augtyro obtained an indication for the treatment of adult and pe",
    "url": "https://finnhub.io/api/news?id=d8b3b503dbb3be5963d041f786b5300452120cf78e8933ff2af818c63107a689",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751887800,
      "headline": "Onco360 Has Been Selected as a National Specialty Pharmacy for Augtyro™ (repotrectinib)",
      "id": 135786238,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "LOUISVILLE, Ky., July 07, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol Myers Squibb to its comprehensive list of limited distribution therapies. Augtyro was initially approved on November 15, 2023, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). In June 2024, Augtyro obtained an indication for the treatment of adult and pe",
      "url": "https://finnhub.io/api/news?id=d8b3b503dbb3be5963d041f786b5300452120cf78e8933ff2af818c63107a689"
    }
  }
]